Treatments for dementia

Alzheimer's disease (AD) and other diseases that cause dementia are the greatest health and social care challenges of our age. Today, there are 50 million people living with dementia worldwide, and this is projected to increase to 135 million by 2050 because of a rise in life expectancy and an aging population. Current therapeutics for AD can transiently improve cognitive symptoms in some patients, but they do not treat the underlying causes of dementia or slow the rate of disease progression. Because the success rate for the development of disease-modifying drugs for dementia diseases has been disappointing, such as the failure of beta-secretase 1 inhibitors to show efficacy, it is important to reconsider what the real barriers to progress in this field are and identify emerging opportunities.

Currently, only symptomatic treatments for dementia are available. At best, they transiently provide limited cognitive benefit in approximately 40% of people living with dementia, and they have no impact on the underlying disease processes or the rate of cognitive decline. While development of symptomatic treatments has slowed, the search for dementia-preventing or dementia-modifying treatments has increased significantly. A plethora of innovative approaches to drug discovery are emerging, with the identification of putative novel mechanisms and potential drug targets being published in high profile journals. However, robust and reproducible biological validation of potential new molecular targets is key to successful and productive drug discovery. However, translating the early novel biology findings into robust drug-target validation is often met with failure, and there are still many significant barriers to successful drug development. The reasons for this are many fold, including incentives to publish preclinical work without the necessary robust evidence for relevance of applicability to human disease; fundamental differences in the biology and degeneration of brain cells in different species; and limitations in the human disease models and outcomes.

A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.scholarscentral.org/submissions/asian-biomedical-pharmaceutical-sciences.html) or forwarded to the Editorial Office at  jbiopharm@scholarlypub.com.

Media Contact:   

Alina Grace            

Journal Manager

Asian Journal of Biomedical & Pharmaceutical Sciences

Email: jbiopharm@scholarlypub.com